A phase 1b open‐label study of sodium selenate as a disease‐modifying treatment for possible behavioral variant frontotemporal dementia

Abstract Introduction Sodium selenate increases tau dephosphorylation through protein phosphatase 2 activation. Here we report an open‐label Phase 1b study of sodium selenate as a disease‐modifying treatment for behavioral variant frontotemporal dementia (bvFTD). Methods Twelve participants with bvF...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Lucy Vivash, Charles B. Malpas, Christian Meletis, Meghan Gollant, Dhamidhu Eratne, Qiao‐Xin Li, Stuart McDonald, William T. O'Brien, Amy Brodtmann, David Darby, Christopher Kyndt, Mark Walterfang, Christopher M. Hovens, Dennis Velakoulis, Terence J. O'Brien
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2022-01-01
coleção:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Assuntos:	anti‐tau treatment behavioral variant frontotemporal dementia (bvFTD) clinical trial fluid biomarkers frontotemporal lobar degeneration (FTLD) magnetic resonance imaging (MRI)
Acesso em linha:	https://doi.org/10.1002/trc2.12299
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!